Ono Pharmaceutical Co., Ltd. has submitted the manufacturing and marketing application for etelcalcetide hydrochloride, or ONO-5163, calcimimetic agent, to seek an indication for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis, in Japan. Etelcalcetide hydrochloride activates calcium sensing receptor in the parathyroid and suppresses excessive PTH secretion, and also lowers phosphorus and serum calcium level. Etelcalcetide hydrochloride is currently developed in an intravenous formulation to be administered through dialysis circuit by physician or medical staff upon completion of dialysis and such administration is expected to reduce the burden of medication in patients.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,220 JPY | -0.43% |
|
+5.31% | -11.76% |
06-11 | Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion | DJ |
06-11 | Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.76% | 6.52B | |
+20.13% | 43.67B | |
+25.15% | 22.79B | |
+19.25% | 15.45B | |
+18.32% | 14.29B | |
+55.47% | 12.83B | |
-0.05% | 6.79B | |
+12.62% | 5.59B | |
-8.87% | 5.73B | |
+9.77% | 4.73B |
- Stock Market
- Equities
- 4528 Stock
- News Ono Pharmaceutical Co., Ltd.
- Ono Pharmaceutical Co., Ltd. Submits Marketing Application for Secondary Hyperparathyroidism Drug